GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Standard BioTools Inc (NAS:LAB) » Definitions » PS Ratio

LAB (Standard BioTools) PS Ratio : 2.62 (As of Dec. 14, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Standard BioTools PS Ratio?

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Standard BioTools's share price is $1.91. Standard BioTools's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.73. Hence, Standard BioTools's PS Ratio for today is 2.62.

The historical rank and industry rank for Standard BioTools's PS Ratio or its related term are showing as below:

LAB' s PS Ratio Range Over the Past 10 Years
Min: 0.7   Med: 2.16   Max: 10.87
Current: 2.71

During the past 13 years, Standard BioTools's highest PS Ratio was 10.87. The lowest was 0.70. And the median was 2.16.

LAB's PS Ratio is ranked better than
56.4% of 805 companies
in the Medical Devices & Instruments industry
Industry Median: 3.29 vs LAB: 2.71

Standard BioTools's Revenue per Sharefor the three months ended in Sep. 2024 was $0.12. Its Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 was $0.73.

Warning Sign:

Standard BioTools Inc revenue per share has been in decline for the last 5 years.

During the past 12 months, the average Revenue per Share Growth Rate of Standard BioTools was -45.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was -11.20% per year. During the past 5 years, the average Revenue per Share Growth Rate was -13.00% per year. During the past 10 years, the average Revenue per Share Growth Rate was -11.00% per year.

During the past 13 years, Standard BioTools's highest 3-Year average Revenue per Share Growth Rate was 62.90% per year. The lowest was -45.50% per year. And the median was -10.70% per year.

Back to Basics: PS Ratio


Standard BioTools PS Ratio Historical Data

The historical data trend for Standard BioTools's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Standard BioTools PS Ratio Chart

Standard BioTools Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
PS Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.98 3.13 2.28 0.94 1.65

Standard BioTools Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.18 1.65 2.29 1.91 2.64

Competitive Comparison of Standard BioTools's PS Ratio

For the Medical Devices subindustry, Standard BioTools's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Standard BioTools's PS Ratio Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Standard BioTools's PS Ratio distribution charts can be found below:

* The bar in red indicates where Standard BioTools's PS Ratio falls into.



Standard BioTools PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Standard BioTools's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=1.91/0.73
=2.62

Standard BioTools's Share Price of today is $1.91.
Standard BioTools's Revenue per Share for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.73.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.


Standard BioTools  (NAS:LAB) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Standard BioTools PS Ratio Related Terms

Thank you for viewing the detailed overview of Standard BioTools's PS Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Standard BioTools Business Description

Traded in Other Exchanges
Address
2 Tower Place, Suite 2000, South San Francisco, CA, USA, 94080
Standard BioTools Inc develops, manufactures, and sells technologies that help biomedical researchers in their search for developing medicines faster. Its tools provide insights into health and disease using proprietary mass cytometry and microfluidics technologies, which serve applications in proteomics and genomics, respectively. Its segments include Proteomics and Genomics. It generates maximum revenue from the Proteomics segment. Geographically, it derives a majority of its revenue from the Americas.
Executives
Casdin Partners Master Fund, L.p. director, 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Martin D Madaus director 290 CONCORD ROAD, BILLERICA MA 01821
Jeffrey G. Black officer: SVP & Chief Financial Officer 4955 DIRECTORS PLACE, SAN DIEGO CA 92121
Eli Casdin director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Partners Fo1-msv, Lp director C/O CASDIN PARTNERS GP, LLC, 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Private Growth Equity Fund Ii Gp, Llc director 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Partners Gp, Llc director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Capital, Llc director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Casdin Private Growth Equity Fund Ii, L.p. director 1350 AVENUE OF THE AMERICAS, SUITE 2600, NEW YORK NY 10019
Fenel M Eloi director C/O INTERLEUKIN GENETICS INC, 135 BEAVER STREET, WALTHAM MA 02452
Caligan Partners Lp 10 percent owner 515 MADISON AVENUE, 8TH FLOOR, NEW YORK NY 10022
Frank Witney director 940 WINTER STREET, C/O PERKINELMER, WALTHAM MA 02451
Jeremy Steven Davis officer: SVP Chief Commercial Officer C/O FLUIDIGM CORPORATION, 2 TOWER PLACE, SUITE 2000, SOUTH SAN FRANCISCO CA 94080
Hanjoon Alex Kim officer: Chief Operating Officer C/O FLUIDIGM CORPORATION, 2 TOWER PLACE, SUITE 2000, SOUTH SAN FRANCISCO CA 94080
Michael Egholm director, officer: President & CEO 1 FRANKLIN STREET, UNIT 3104, BOSTON MA 02110